Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: Implications for Alzheimer's disease
Article first published online: 3 MAR 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Neuroscience Research
Volume 89, Issue 6, pages 808–814, June 2011
How to Cite
Sutcliffe, J. G., Hedlund, P. B., Thomas, E. A., Bloom, F. E. and Hilbush, B. S. (2011), Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: Implications for Alzheimer's disease. J. Neurosci. Res., 89: 808–814. doi: 10.1002/jnr.22603
- Issue published online: 13 APR 2011
- Article first published online: 3 MAR 2011
- Manuscript Revised: 31 DEC 2010
- Manuscript Accepted: 31 DEC 2010
- Manuscript Received: 18 NOV 2010
- Alzheimer's disease;
Three loci that modify β-amyloid (Aβ) accumulation and deposition in the brains of a mouse model of Alzheimer's disease have been previously described. One encompasses the Psen2 gene encoding presenilin 2, a component of the γ-secretase activity responsible for generating Aβ by proteolysis. We show that the activity of mouse Psen2, as measured by levels of mRNA accumulation, unexpectedly is heritable in the liver but not the brain, suggesting liver as the origin of brain Aβ deposits. Administration of STI571, a cancer therapeutic that does not cross the blood–brain barrier, reduced accumulation of Aβ in both the blood and the brain, confirming brain Aβ's peripheral origin and suggesting that STI571 and related compounds might have therapeutic/prophylactic value in human Alzheimer's disease. The genes Cib1 and Zfhx1b reside within the other modifier loci and also exhibit heritable expression in the liver, suggesting that they too contribute to Aβ accumulation. © 2011 Wiley-Liss, Inc.